Quarterly Result12 Feb 2026, 11:32 am
Lincoln Pharmaceuticals Ltd. Approves Un-Audited Financial Results for Q3 and Nine Months Ended on December 31, 2025
AI Summary
Lincoln Pharmaceuticals Ltd. held a Board Meeting on February 12, 2026, where they considered and approved the un-audited financial results for the quarter and nine months ended on December 31, 2025. The total income for the nine months ended on December 31, 2025, was 52,140.19 lakhs, with a profit before tax of 9,176.17 lakhs. The consolidated financial results include the results of the single business segment, Pharmaceutical Business, and the subsidiary, Zullinc Healthcare LLP. The auditor has carried out a limited review of the financial results.
Key Highlights
- Un-audited financial results for Q3 and nine months ended on December 31, 2025, approved
- Total income for the nine months ended on December 31, 2025, was 52,140.19 lakhs
- Profit before tax for the nine months ended on December 31, 2025, was 9,176.17 lakhs
- Pharmaceutical Business is the single business segment
- Zullinc Healthcare LLP is a subsidiary of Lincoln Pharmaceuticals Ltd.
Price Impact
More from LINCOPH